JBIOHealthcare · BiotechnologyJBIO Stock Forecast: Jade Biosciences, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Jade Biosciences, Inc. hold a median 12-month price target of $45 — +135.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
JBIO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Jade Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (77): The shares have been drifting up relative to others.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Jade Biosciences, Inc. — and when they’d sell — is the membership.
JBIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on JBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +135.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 June 2026 | UBS | Initiates | Buy | $45 |
| 2 June 2026 | Wedbush | Maintains | Outperform | — |
| 1 June 2026 | BTIG | Maintains | Buy | — |
| 1 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 May 2026 | BTIG | Reiterates | Buy | — |
| 11 May 2026 | Guggenheim | Maintains | Buy | — |
| 11 May 2026 | Wedbush | Maintains | Outperform | — |
| 27 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Mar 2026 | BTIG | Maintains | Buy | — |
| 11 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 9 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 7 Jan 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 25 Nov 2025 | Clear Street | Initiates | Buy | — |
| 18 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 9 Oct 2025 | BTIG | Initiates | Buy | — |
| 14 Aug 2025 | Wedbush | Maintains | Outperform | — |
| 16 June 2025 | Guggenheim | Upgrade | Buy | — |
| 15 May 2025 | Wedbush | Reiterates | Outperform | — |
| 7 May 2025 | Wedbush | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
JBIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Jade Biosciences, Inc. (JBIO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −6.2×
- Price / sales
- —
- Price / book
- 3.3×
- EV / EBITDA
- −5.9×
Cheaper than 91% of US stocks
Cheaper than 31% of US stocks
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −38.3%
- Return on assets
- −36.4%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
JBIO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JBIO appears on the weeks it earns a place.
Frequently asked questions about JBIO stock
What is the JBIO stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Jade Biosciences, Inc. have a median 12-month price target of $45, with estimates ranging from $40 to $74. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is JBIO stock a buy right now?
Of the 10 analysts covering Jade Biosciences, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jade Biosciences, Inc. 22 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank JBIO?
As at 1 Aug 2026, Jade Biosciences, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (77 of 100).
Will JBIO stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +135.0% from the last close, and Ticker Nerd's factor model ranks Jade Biosciences, Inc. 22 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the JBIO stock forecast for 2030?
No analyst covering Jade Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $74 over the next 12 months.
How has JBIO stock performed over the past year?
Jade Biosciences, Inc. returned +177.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Jade Biosciences, Inc. do?
Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for inflammation and immunology indications in patients with autoimmune diseases.
About Jade Biosciences, Inc.
Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for inflammation and immunology indications in patients with autoimmune diseases. Its lead candidate, JADE101, is a monoclonal antibody designed to inhibit the cytokine APRIL (A Proliferation-Inducing Ligand) and targets immunoglobulin A nephropathy (IgAN), a chronic kidney disease that damages kidney function by promoting harmful IgA antibodies and proteinuria. The company's pipeline also features JADE201, an anti-BAFF-R (B-cell activating factor receptor) program, and JADE301, an undisclosed antibody initiative, all aimed at creating potentially best-in-class, disease-modifying biologics. Jade Biosciences Inc. builds on discovery-stage assets licensed from Paragon Therapeutics to address critical unmet needs in autoimmune conditions. Incorporated in 2024 and headquartered in Waltham, Massachusetts, the company operates in the healthcare sector, advancing its programs through clinical trials including ongoing Phase 1 studies for JADE101 with planned Phase 2 initiation.
CEO Mr. Tom Frohlich · 55 employees · United States · https://jadebiosciences.com